Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883 · View on ClinicalTrials.gov ↗
Study Summary
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Conditions Studied
Interventions
- PROCEDURE Wide Local Excision = 1cm Margin
- PROCEDURE Wide Local Excision = 2cm Margin
Study Locations (20)
California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine
- Los Angeles General Medical Center — Los Angeles
- Los Angeles General Medical Center — Los Angeles
- USC Norris Comprehensive Cancer Center — Los Angeles
- USC Norris Comprehensive Cancer Center — Los Angeles
- The Angeles (Cedars-Sinai Medical Center and its Affiliates) — Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Orange
- Stanford Cancer Institute — Palo Alto
- Huntington Memorial Hospital — Pasadena
- Stanford Cancer Center South Bay — San Jose
- Kaiser Permanente - Vallejo Medical Center — Vallejo
- Kaiser Permanente - Walnut Creek Medical Center — Walnut Creek
Arizona
- Banner MD Anderson Cancer Center — Gilbert
- Mayo Clinic Phoenix — Phoenix
Connecticut
- Smilow Hospital Care Center, Guilford — Guilford
- Yale University — New Haven
Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile
Arkansas
- University of Arkansas for Medical Sciences — Little Rock
District of Columbia
- MedStar Georgetown University Hospital — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,998 participants |
| Start Date | 2019-12-17 |
| Est. Completion | 2034-12-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03860883
The ClinicalTrials.gov registry entry for NCT03860883 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,998 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melanoma and Skin Cancer Trials Limited, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cutaneous Melanoma, Stage II appearing as the primary indexed condition, and to 2 interventions — of which Wide Local Excision = 1cm Margin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03860883 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Arizona, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03860883 about?
NCT03860883 is a clinical study titled "Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma". Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for ...
What is the current status of trial NCT03860883?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,998 participants. The study started on 2019-12-17. Estimated completion is 2034-12-31.
What conditions does trial NCT03860883 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Stage II. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03860883?
The interventions under investigation include: Wide Local Excision = 1cm Margin (PROCEDURE), Wide Local Excision = 2cm Margin (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03860883?
This trial is sponsored by Melanoma and Skin Cancer Trials Limited, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03860883 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.